Apellis Pharmaceuticals, INC Form 4 insider transactions

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, was granted 45,220 Restricted Stock Units vesting over four years.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, received a grant of 58,140 Restricted Stock Units, vesting annually over four years.

Apellis Pharmaceuticals' General Counsel, David O. Watson, was granted 55,986 Restricted Stock Units vesting over four years.

Apellis Pharmaceuticals CEO Cedric Francois received a grant of 195,952 Restricted Stock Units, vesting over four years.

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 2,797 shares of common stock to cover tax obligations related to RSU vesting.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 2,064 shares of common stock at $21.7654 to cover tax withholding on Restricted Stock Units.

Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, sold 3,371 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold 5,928 shares of common stock to cover tax withholding obligations.

Apellis Pharmaceuticals CEO Cedric Francois sold 27,192 shares of common stock at $21.7654 per share to cover tax withholding obligations related to Restricted Stock Units.

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 7,725 shares of common stock at $21.7654 per share to cover tax withholding on restricted stock units.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, sold 10,287 shares of common stock at $21.7654 per share to cover tax withholding on restricted stock units.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 7,832 shares of common stock to cover tax withholding obligations related to RSU release.

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 1,882 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 726 shares of common stock to cover tax withholding obligations related to RSU vesting.

Apellis Pharmaceuticals' Chief Business & Strategic Officer, Mark DeLong, sold 1,334 shares of common stock to cover tax withholding obligations related to RSU vesting.

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold 909 shares of common stock to cover tax obligations related to Restricted Stock Units.

Apellis Pharmaceuticals CEO Cedric Francois sold 8,182 shares of common stock to cover tax withholding on recently released Restricted Stock Units.

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 2,203 shares of common stock to cover tax obligations related to RSU vesting.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, sold 2,892 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 2,475 shares of common stock at $19.7929 per share to cover tax withholding on restricted stock units.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 873 shares of common stock to cover tax obligations related to RSU vesting.

Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, sold 1,780 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 2,277 shares of common stock to satisfy tax withholding requirements on recently vested Restricted Stock Units.

Apellis Pharmaceuticals CEO Cedric Francois sold 10,186 shares of common stock to cover tax withholding obligations related to restricted stock units.

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 2,618 shares of common stock to cover tax withholding related to restricted stock unit release.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, sold 3,856 shares of common stock to cover tax obligations related to vested restricted stock units.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,780 shares of common stock to cover tax withholding obligations related to restricted stock units.

Apellis Pharmaceuticals' General Counsel, David O. Watson, acquired 888 shares of common stock through the exercise of stock options in a pre-planned transaction.

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 3,020 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Apellis Pharmaceuticals director Alec Machiels was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026.